Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
2382 results:
1. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
Osumi H; Shinozaki E; Nakamura Y; Esaki T; Yasui H; Taniguchi H; Satake H; Sunakawa Y; Komatsu Y; Kagawa Y; Denda T; Shiozawa M; Satoh T; Nishina T; Goto M; Takahashi N; Kato T; Bando H; Yamaguchi K; Yoshino T
Nat Commun; 2024 Jul; 15(1):5885. PubMed ID: 39003289
[TBL] [Abstract] [Full Text] [Related]
2. Epidermal Growth Factor Receptor Targeting in colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
[TBL] [Abstract] [Full Text] [Related]
3. Current and Emerging treatment Paradigms in colorectal cancer: Integrating Hallmarks of cancer.
Salva de Torres C; Baraibar I; Saoudi González N; Ros J; Salva F; Rodríguez-Castells M; Alcaraz A; García A; Tabernero J; Élez E
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000083
[TBL] [Abstract] [Full Text] [Related]
4. Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.
Bajpai P; Agarwal S; Afaq F; Al Diffalha S; Chandrashekar DS; Kim HG; Shelton A; Miller CR; Singh SK; Singh R; Varambally S; Nagaraju GP; Manne A; Paluri R; Khushman M; Manne U
J Exp Clin Cancer Res; 2024 Jul; 43(1):192. PubMed ID: 38992681
[TBL] [Abstract] [Full Text] [Related]
5. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
[TBL] [Abstract] [Full Text] [Related]
6. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
Chen S; Gu J; Wu K; Zhao X; Lu Y
Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
[TBL] [Abstract] [Full Text] [Related]
7. Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of colorectal cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-egfr and Anti-VEGF Therapies.
Popovici D; Stanisav C; Sima LV; Negru A; Murg SI; Carabineanu A
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929620
[No Abstract] [Full Text] [Related]
8. KRASFormer: a fully vision transformer-based framework for predicting
Singh VK; Makhlouf Y; Sarker MMK; Craig S; Baena J; Greene C; Mason L; James JA; Salto-Tellez M; O'Reilly P; Maxwell P
Biomed Phys Eng Express; 2024 Jul; 10(5):. PubMed ID: 38925106
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Cohen R; Raeisi M; Chibaudel B; Shi Q; Yoshino T; Zalcberg JR; Adams R; Cremolini C; Van Cutsem E; Heinemann V; Tabernero J; Punt CJA; Arnold D; Hurwitz HI; Douillard JY; Venook AP; Saltz LB; Maughan TS; Kabbinavar F; Bokemeyer C; Grothey A; Mayer RJ; Kaplan R; Tebbutt NC; Randolph Hecht J; Giantonio BJ; Díaz-Rubio E; Sobrero AF; Peeters M; Koopman M; Goldberg RM; Andre T; de Gramont A
Eur J Cancer; 2024 Aug; 207():114160. PubMed ID: 38896997
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
[TBL] [Abstract] [Full Text] [Related]
11. Novel Lipid Nanocomplex Co-Carrying Bcl2 siRNA and Quantum Dots for EGF Receptor-Targeted Anti-cancer Theranosis.
Choi MJ; Kang SJ; Lee YK; Choi KC; Lee DH; Jeong HY; Kim MW; Kim KS; Park YS
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892434
[TBL] [Abstract] [Full Text] [Related]
12. Targeted treatment against cancer Stem Cells in colorectal cancer.
Martínez-Pérez J; Torrado C; Domínguez-Cejudo MA; Valladares-Ayerbes M
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892410
[TBL] [Abstract] [Full Text] [Related]
13. Genome-wide DNA methylation status is a predictor of the efficacy of anti-egfr antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.
Ouchi K; Takahashi S; Sasaki K; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
Int J Colorectal Dis; 2024 Jun; 39(1):89. PubMed ID: 38862615
[TBL] [Abstract] [Full Text] [Related]
14. Proteomic Analysis of Caco-2 Cells Disrupted by EcN 1917-Derived OMVs Reveals Molecular Information on Bacteria-Mediated cancer Cell Migration.
Zhao L; Zhao M; Wang X; Jia C
J Proteome Res; 2024 Jul; 23(7):2505-2517. PubMed ID: 38845157
[No Abstract] [Full Text] [Related]
15. Brexpiprazole Prevents the Malignant Progression of Human colorectal cancer Cells and Increases Its Sensitivity to egfr Inhibition.
Long X; Liu X; Xia W; Liu L; Chen W
Front Biosci (Landmark Ed); 2024 May; 29(5):174. PubMed ID: 38812296
[TBL] [Abstract] [Full Text] [Related]
16. Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment.
Iguchi K; Shiozawa M; Uchiyama M; Asari M; Numata K; Rino Y; Saito A
J Cancer Res Clin Oncol; 2024 May; 150(5):281. PubMed ID: 38805050
[TBL] [Abstract] [Full Text] [Related]
17. Rechallenge with Anti-egfr treatment in RAS/BRAF wt Metastatic colorectal cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.
Salgado Fernández M; Reboredo López M; Covela Rúa M; Candamio S; González-Villarroel P; Sánchez-Cousido LF; Graña B; Carral-Maseda A; Cameselle-García S; Varela Pose V; Gallardo-Martín ME; Martínez-Lago N;
Target Oncol; 2024 Jul; 19(4):565-573. PubMed ID: 38780742
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
[TBL] [Abstract] [Full Text] [Related]
19. Pharmacokinetic studies, molecular docking, and molecular dynamics simulations of phytochemicals from Morus alba: a multi receptor approach for potential therapeutic agents in colorectal cancer.
Stany B; Mishra S; Rao KVB
Med Oncol; 2024 May; 41(6):156. PubMed ID: 38750377
[TBL] [Abstract] [Full Text] [Related]
20. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
[Next]
